26 Sep 2013 07:00
26 September, 2013
BIOQUELL PLC
Resignation of Mark Bodeker,Group Finance Director and Chief Operating Officer
Bioquell PLC ("Bioquell") (LSE symbol: BQE), provider of specialist bio-contamination control technologies to the international Healthcare, Life Sciences & Defence markets; and specialist testing services in the UK via its TRaC division, announces that Mark Bodeker, the Group's Finance Director and Chief Operating Officer, has decided that he will resign from Bioquell to pursue other interests. He will leave the Group in March 2014 at the end of his six months' notice period.
The Group has started to recruit a new Finance Director.
***************
Nigel Keen, Chairman of Bioquell PLC, said:
"Mark has been a key member of the senior team at Bioquell for the last 13 years."
"During his tenure Bioquell has grown from revenues of some £15 million in 2000 to £41 million in 2012."
"We wish Mark every success with his future career."
- Ends -
Enquiries:
Bioquell PLC 01264 835 900
Nigel Keen Chairman
Nick Adams Group Chief Executive
Mark Bodeker Chief Operating Officer / Finance Director
Notes to editors:
§ Bioquell is a UK-headquartered, international technology company with two divisions:
o Bio-decon (www.bioquell.com) which sells specialist bio-contamination control products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and
o TRaC (www.tracglobal.com) which provides specialist Testing, Regulatory and Compliance services - including EMC, environmental and safety testing - principally to UK corporates.
§ Bioquell's bio-contamination control technology is principally based around hydrogen peroxide vapour ("HPV") - which is highly efficacious at eradicating micro-organisms such as bacteria and viruses at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen (hence an extremely 'green' technology) at the end of the bio-decontamination process.
§ For the last two years Bioquell has invested substantial sums in developing a new product range which has been designed to increase the proportion of recurring revenues from its HPV technology - and hence increase its quality of earnings; this range of new products was launched in the second half of 2012.
§ Bioquell's bio-contamination control technology:
o is used by bio-pharmaceutical, biotechnology and research institutions to provide sterile equipment and/or sterile working environments;
o is used to eradicate "superbugs" from hospitals; independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces significantly the rates of hospital acquired infection;
o is used to provide single rooms to hospitals (via the ICE-pod) which currently only have open, multi-bed "Nightingale" ward structures
o has been incorporated in a wound-care product - BioxyQuell - which has received regulatory approval for use on chronic wounds in the European Union; and
§ Bioquell currently has overseas operations in the USA, France, Ireland, Singapore, China and Brazil.
TRaC sells its specialist services to the product development departments of a broad range of companies, principally based in the UK, with a particular focus on organisations operating in the aerospace and defence sectors.